Tuesday, May 8, 2018 4:30 pm EDT NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 2:20
April 11, 2018 – WTX101 is in Phase 3 Development as a Novel Treatment for Wilson Disease, a Rare, Genetic, and Chronic Copper-Mediated Liver Disorder – – Conference Call and Webcast Scheduled for Today, April 11, 2018 at 8:30 a.m.
March 15, 2018 — ALXN1210 Achieved Non-Inferiority to Soliris ® (Eculizumab) on Co-Primary Endpoints of Transfusion Avoidance and Lactate Dehydrogenase Normalization, and All Four Key Secondary Endpoints — — Safety Profile of ALXN1210 Consistent with That Seen for Soliris ® — — Regulatory Submissions
February 27, 2018 BOSTON & NEW HAVEN, Conn.–(BUSINESS WIRE)–The Manton Center for Orphan Disease Research, the Innovation and Digital Health Accelerator at Boston Children’s Hospital, and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced a collaboration to enable rapid and precise diagnoses
February 6, 2018 NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive lysosomal acid lipase